로딩 중…
지수 로딩 중…
SAMSUNG BIOLOGICS CO.,LTD.
207940· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,374,000-3.92%
2026-06-19
Price Chart
SAMSUNG BIOLOGICS CO.,LTD.-6.55%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 63.60T KRW |
| Revenue | 4.52T KRW |
| Net Income | 1.88T KRW |
| Total Assets | 11.99T KRW |
| Net Assets | 7.92T KRW |
| Employees | 5,011 |
| Value | |
| P/E | 33.87x |
| P/B | 8.03x |
| PEG | 1.36x |
| P/S | 14.08x |
| EV/EBITDA | 135.56x |
| FCF Yield | 1.35% |
| Profitability | |
| ROE | 23.70% |
| ROA | 15.66% |
| Op. Margin | 47.90% |
| Revenue Growth | -3.17% |
| Earnings Growth | 24.95% |
| Financial Health | |
| Debt Ratio | 51.40% |
| Total Debt | 918.90B KRW |
| FCF | 856.07B KRW |
| Cash | 520.36B KRW |
| Current Ratio | 1.70x |
| Net Debt/EBITDA | 0.84x |
| Performance | |
| 1Y Return | -6.55% |
| 1M Return | 2.77% |
| From 52W High | -30.85% |
| 1Y MDD | -36.74% |
| Trading | |
| Volume | 96,732 shares |
| Foreign Own. | 12.43% |
| Per Share | |
| EPS | 30,779 KRW |
| BPS | 171,343 KRW |
Company Info
CEO 임존종보 (Rim John Chongbo)
Employees 5,011
Founded 2011
HQ 인천광역시 연수구, KR
Website www.samsungbiologics.com
Established in 2011, this company is a biopharmaceutical CDMO specialist that incorporated development and commercialization divisions by acquiring 100% of Samsung Bioepis shares in 2022. It operates production facilities in Songdo, Incheon, offering contract manufacturing and cell line/process development services, and currently sells 10 types of biosimilars globally. The company is expanding from antibody drug-focused CDMO to next-generation biopharmaceuticals, aiming to complete an End-to-End service system with the launch of an organoid business in 2025. Samsung Biologics is headquartered in Yeonsu-gu, Incheon.